These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 21878538)
1. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538 [TBL] [Abstract][Full Text] [Related]
2. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer. Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091 [TBL] [Abstract][Full Text] [Related]
3. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808 [TBL] [Abstract][Full Text] [Related]
4. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Dubrovska A; Hartung A; Bouchez LC; Walker JR; Reddy VA; Cho CY; Schultz PG Br J Cancer; 2012 Jun; 107(1):43-52. PubMed ID: 22644306 [TBL] [Abstract][Full Text] [Related]
5. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells]. Zhang YH; Li G; Yu J; Xu MS; Liu ZX Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells. Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496 [TBL] [Abstract][Full Text] [Related]
8. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Imai Y; Ishikawa E; Asada S; Sugimoto Y Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404 [TBL] [Abstract][Full Text] [Related]
9. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance. Busch S; Sims AH; Stål O; Fernö M; Landberg G Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830 [TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324 [TBL] [Abstract][Full Text] [Related]
11. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells. Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276 [TBL] [Abstract][Full Text] [Related]
12. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261 [TBL] [Abstract][Full Text] [Related]
14. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro. Xiong H; Jin X; You C Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994 [TBL] [Abstract][Full Text] [Related]
16. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559 [TBL] [Abstract][Full Text] [Related]
17. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells. Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334 [TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079 [TBL] [Abstract][Full Text] [Related]
19. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells. Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]